PROTOCOL ALD-102 AN OPEN LABEL, NON-RANDOMIZED, SINGLE DOSE, MULTI-CENTER PHASE 2 3 STUDY OF THE SAFETY AND EFFICACY OF LENTI-D MODIFIED AUTOLOGOUS STEM CELLS (LENTI-D DRUG PRODUCT) FOR THE TREATMENT OF SUBJECTS WITH CHI - Peroxisomal disorders - Document - PDFSEARCH.IO

First Page	Meta Content
	PROTOCOL ALD-102 AN OPEN LABEL, NON-RANDOMIZED, SINGLE DOSE, MULTI-CENTER PHASE 2/3 STUDY OF THE SAFETY AND EFFICACY OF LENTI-D MODIFIED AUTOLOGOUS STEM CELLS (LENTI-D DRUG PRODUCT) FOR THE TREATMENT OF SUBJECTS WITH CHI Add to Reading List Document Date: 2013-12-31 13:09:44 Open Document File Size: 2,77 MB Share Result on Facebook Facility Children’s Hospital / / IndustryTerm clinical protocol / / MedicalCondition Childhood Cerebral Adrenoleukodystrophy / FOR THE TREATMENT OF SUBJECTS WITH CHILDHOOD CEREBRAL ADRENOLEUKODYSTROPHY / also various neurologic deficits / neurologic deficits / Disease / adrenal insufficiency / / MedicalTreatment clinical protocol / / Organization Children’s Hospital Boston Harvard Medical School / / Person David A. Williams / / Technology MRI / STEM CELLS / / URL http / SocialTag Peroxisomal disorders Rare diseases Adrenoleukodystrophy Leukodystrophies Hematopoietic stem cell transplantation Myelin Medicine Health Biology

PROTOCOL ALD-102 AN OPEN LABEL, NON-RANDOMIZED, SINGLE DOSE, MULTI-CENTER PHASE 2/3 STUDY OF THE SAFETY AND EFFICACY OF LENTI-D MODIFIED AUTOLOGOUS STEM CELLS (LENTI-D DRUG PRODUCT) FOR THE TREATMENT OF SUBJECTS WITH CHIAdd to Reading List